NWO-VENI laureate Prof. Hak and his multidisciplinary team have supervised >30 PhD theses on the validity of scientific statistical and epidemiological causal design methods to assess (side-) effects of drugs and vaccines using Real-World Big Health Care and Biobank Data. Scientific methods consider a variety of designs such as case-control, cohort, case-only, sibling designs, instrumental variable analysis, propensity score analysis often in combination with RCTs, meta-analyses and Individual Patient Data designs. His scientific work led to >400 peer-reviewed publications till 2021 (Web of Science H-index 44, >8,000 citations). As leader of the PharmLines Initiative, a public-private collaboration between Lifelines BV-UMCG-RUG, he initiates and co-supervises research in the area of Precision Medicine with linked biobank, genetic, clinical, pharmacological and health care data of >80,000 persons from the Northern region. Topics mainly concern the pharmaco-epidemiology of preventive medications as well as vaccinations. In addition, his team supports the societal impact by studying the optimal methods to implement innovations in the area of sustainable drug applications and vaccination strategies (e.g. drug repurposing, data science technologies to support optimal drug use, development of infection risk profiles and vaccination passport).